Nurix Therapeutics Stock Performance
| NRIX Stock | USD 19.14 0.35 1.80% |
The company secures a Beta (Market Risk) of 0.85, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Nurix Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Nurix Therapeutics is expected to be smaller as well. At this point, Nurix Therapeutics has a negative expected return of -0.39%. Please make sure to verify Nurix Therapeutics' maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Nurix Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nurix Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (1.80) | Five Day Return 5.8 | Year To Date Return (1.90) | Ten Year Return 0.68 | All Time Return 0.68 |
1 | Disposition of 1924 shares by Christine Ring of Nurix Therapeutics subject to Rule 16b-3 | 10/30/2024 |
2 | Disposition of 3290 shares by Christine Ring of Nurix Therapeutics at 25.0 subject to Rule 16b-3 | 11/04/2024 |
3 | Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hemato... | 12/02/2024 |
4 | Where are the Opportunities in - Stock Traders Daily | 12/05/2024 |
5 | Nurix Therapeutics Presents New Positive Data from Phase 1a1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematolo... | 12/09/2024 |
6 | Is Nurix Therapeutics the Worst ARK Stock to Buy According to Short Sellers | 12/11/2024 |
7 | Nurix Therapeutics SWOT analysis btk degrader stock shows promise amid challenges | 12/17/2024 |
8 | Nurix Therapeutics Inc Receives FDA Fast Track Designation for NX-5948 | 12/19/2024 |
9 | Disposition of 5760 shares by Christine Ring of Nurix Therapeutics at 19.4956 subject to Rule 16b-3 | 01/02/2025 |
10 | Nurix Therapeutics to Participate in the43rd Annual J.P. Morgan Healthcare Conference | 01/06/2025 |
11 | Nurix Therapeutics Inc Announces Strategic Plans for 2025 at J.P. ... | 01/13/2025 |
12 | Nurix Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating - Inkl | 01/14/2025 |
| Begin Period Cash Flow | 65.4 M |
Nurix |
Nurix Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,548 in Nurix Therapeutics on October 20, 2024 and sell it today you would lose (634.00) from holding Nurix Therapeutics or give up 24.88% of portfolio value over 90 days. Nurix Therapeutics is currently does not generate positive expected returns and assumes 3.6863% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Nurix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nurix Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nurix Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nurix Therapeutics, and traders can use it to determine the average amount a Nurix Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1064
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NRIX |
Estimated Market Risk
| 3.69 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.39 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Nurix Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nurix Therapeutics by adding Nurix Therapeutics to a well-diversified portfolio.
Nurix Therapeutics Fundamentals Growth
Nurix Stock prices reflect investors' perceptions of the future prospects and financial health of Nurix Therapeutics, and Nurix Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nurix Stock performance.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (4.34) % | ||||
| Current Valuation | 959.69 M | ||||
| Shares Outstanding | 70.84 M | ||||
| Price To Book | 3.66 X | ||||
| Price To Sales | 24.47 X | ||||
| Revenue | 76.99 M | ||||
| Gross Profit | (147.7 M) | ||||
| EBITDA | (141.41 M) | ||||
| Net Income | (143.95 M) | ||||
| Cash And Equivalents | 344.48 M | ||||
| Cash Per Share | 7.31 X | ||||
| Total Debt | 30.61 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 5.26 X | ||||
| Book Value Per Share | 5.62 X | ||||
| Cash Flow From Operations | (81.36 M) | ||||
| Earnings Per Share | (2.85) X | ||||
| Market Capitalization | 1.38 B | ||||
| Total Asset | 355.6 M | ||||
| Retained Earnings | (545.2 M) | ||||
| Working Capital | 208.54 M | ||||
About Nurix Therapeutics Performance
Evaluating Nurix Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Nurix Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nurix Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (42.72) | (40.58) | |
| Return On Tangible Assets | (0.47) | (0.49) | |
| Return On Capital Employed | (0.52) | (0.55) | |
| Return On Assets | (0.47) | (0.49) | |
| Return On Equity | (0.83) | (0.78) |
Things to note about Nurix Therapeutics performance evaluation
Checking the ongoing alerts about Nurix Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nurix Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nurix Therapeutics generated a negative expected return over the last 90 days | |
| Nurix Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 76.99 M. Net Loss for the year was (143.95 M) with loss before overhead, payroll, taxes, and interest of (147.7 M). | |
| Nurix Therapeutics currently holds about 344.48 M in cash with (81.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.31. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Nurix Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating - Inkl |
- Analyzing Nurix Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nurix Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Nurix Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nurix Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nurix Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nurix Therapeutics' stock. These opinions can provide insight into Nurix Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.